[{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Monoclonal Antibodies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"Vesigen Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"ARMMs based cell and gene therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vesigen Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Vesigen Therapeutics \/ Bayer","highestDevelopmentStatusID":"3","companyTruncated":"Vesigen Therapeutics \/ Bayer"},{"orgOrder":0,"company":"Cyclica","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cyclica","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cyclica \/ Cerevel Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cyclica \/ Cerevel Therapeutics"},{"orgOrder":0,"company":"Vyripharm Biopharmaceuticals","sponsor":"National Yang-Ming University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"VYR-206","moa":"CB1","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Vyripharm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Vyripharm Biopharmaceuticals \/ National Yang-Ming University","highestDevelopmentStatusID":"3","companyTruncated":"Vyripharm Biopharmaceuticals \/ National Yang-Ming University"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"AAV vectors based gene therapies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Dyno Therapeutics","amount2":1.8,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.8,"dosageForm":"","sponsorNew":"Dyno Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Dyno Therapeutics \/ Roche"},{"orgOrder":0,"company":"Wren Therapeutics","sponsor":"Eisai Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Alpha synuclein aggregation","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Wren Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Wren Therapeutics \/ Eisai","highestDevelopmentStatusID":"3","companyTruncated":"Wren Therapeutics \/ Eisai"},{"orgOrder":0,"company":"Tevard Biosciences","sponsor":"Zogenix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"tRNA-based gene therapies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Tevard Biosciences","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"","sponsorNew":"Tevard Biosciences \/ Zogenix","highestDevelopmentStatusID":"3","companyTruncated":"Tevard Biosciences \/ Zogenix"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Skyhawk Therapeutics","amount2":2.2400000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":2.2400000000000002,"dosageForm":"","sponsorNew":"Skyhawk Therapeutics \/ Vertex","highestDevelopmentStatusID":"3","companyTruncated":"Skyhawk Therapeutics \/ Vertex"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Cevec","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cevec \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Biogen"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"saRNA therapies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Mina Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Mina Therapeutics \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Mina Therapeutics \/ Servier"},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"Sosei Heptares","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Metrion Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Metrion Biosciences \/ Sosei Heptares","highestDevelopmentStatusID":"3","companyTruncated":"Metrion Biosciences \/ Sosei Heptares"},{"orgOrder":0,"company":"IRICoR","sponsor":"Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"IRICoR","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"IRICoR \/ Universit\u00e9 de Montr\u00e9al","highestDevelopmentStatusID":"3","companyTruncated":"IRICoR \/ Universit\u00e9 de Montr\u00e9al"},{"orgOrder":0,"company":"Oxford Drug Discovery","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"NLRP3","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Oxford Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Oxford Drug Discovery \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Drug Discovery \/ Exscientia"},{"orgOrder":0,"company":"Alchemab","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Series A Financing","leadProduct":"Antibody","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Alchemab \/ RA Capital Management","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ RA Capital Management"},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsida","amount2":0.62,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.62,"dosageForm":"","sponsorNew":"Capsida \/ AbbVie","highestDevelopmentStatusID":"3","companyTruncated":"Capsida \/ AbbVie"},{"orgOrder":0,"company":"Capsigen","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV capsids based gene therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Capsigen","amount2":1.3100000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.3100000000000001,"dosageForm":"","sponsorNew":"Capsigen \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"Capsigen \/ Biogen"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Capsida","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"CRISPR Therapeutics \/ Capsida Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"CRISPR Therapeutics \/ Capsida Biotherapeutics"},{"orgOrder":0,"company":"Muna Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Progranulin pathway","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Muna Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Muna Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Muna Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"RNA","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"","sponsorNew":"Rgenta Therapeutics \/ Lundbeck","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta Therapeutics \/ Lundbeck"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Shape Therapeutics","amount2":3,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":3,"dosageForm":"","sponsorNew":"Shape Therapeutics \/ Roche","highestDevelopmentStatusID":"3","companyTruncated":"Shape Therapeutics \/ Roche"},{"orgOrder":0,"company":"SciNeuro Pharmaceuticals","sponsor":"Mabylon","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Human Auto-antibodies","moa":"TDP-43","graph1":"Neurology","graph2":"Discovery Platform","graph3":"SciNeuro Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"SciNeuro Pharmaceuticals \/ Mabylon","highestDevelopmentStatusID":"3","companyTruncated":"SciNeuro Pharmaceuticals \/ Mabylon"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"Antisense Oligonucleotides","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Denali Therapeutics \/ Secarna","highestDevelopmentStatusID":"3","companyTruncated":"Denali Therapeutics \/ Secarna"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Recursion Pharma","amount2":12.15,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":12.15,"dosageForm":"","sponsorNew":"Recursion Pharma \/ Roche ","highestDevelopmentStatusID":"3","companyTruncated":"Recursion Pharma \/ Roche "},{"orgOrder":0,"company":"Verge Genomics","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Verge Genomics \/ BlackRock","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ BlackRock"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Ion channel","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ligand Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.26000000000000001,"dosageForm":"","sponsorNew":"Ligand Pharmaceuticals \/ GlaxoSmithKline","highestDevelopmentStatusID":"3","companyTruncated":"Ligand Pharmaceuticals \/ GlaxoSmithKline"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Human-derived Monoclonal Antibodies","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Neurimmune \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Neurimmune \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.28999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.28999999999999998,"dosageForm":"","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"GliaPharm","sponsor":"Wyss Center","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"GliaPharm","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"GliaPharm \/ Wyss Center","highestDevelopmentStatusID":"3","companyTruncated":"GliaPharm \/ Wyss Center"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"RNA Therapeutic","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rona Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ Lilly Asia Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rona Therapeutics \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Plexium","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Plexium \/ AbbVie","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ AbbVie"},{"orgOrder":0,"company":"Biogen","sponsor":"Envisagenics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biogen \/ Envisagenics","highestDevelopmentStatusID":"3","companyTruncated":"Biogen \/ Envisagenics"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.33000000000000002,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Pfizer"},{"orgOrder":0,"company":"Captor Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Captor Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.20000000000000001,"dosageForm":"","sponsorNew":"Captor Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Captor Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevance","amount2":1.1299999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co. Inc.","highestDevelopmentStatusID":"3","companyTruncated":"Cerevance \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"AAV-based Capsid","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Voyager Therapeutics, Inc","amount2":1.75,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.75,"dosageForm":"","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis","highestDevelopmentStatusID":"3","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis"},{"orgOrder":0,"company":"BridGene Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BridGene Biosciences","amount2":0.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.5,"dosageForm":"","sponsorNew":"BridGene Biosciences \/ Takeda","highestDevelopmentStatusID":"3","companyTruncated":"BridGene Biosciences \/ Takeda"},{"orgOrder":0,"company":"Verge Genomics","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Verge Genomics","amount2":0.88,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.88,"dosageForm":"","sponsorNew":"Verge Genomics \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Verge Genomics \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sumitomo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Salipro Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Salipro Biotech \/ Sumitomo","highestDevelopmentStatusID":"3","companyTruncated":"Salipro Biotech \/ Sumitomo"},{"orgOrder":0,"company":"Cure Genetics","sponsor":"Frametact","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cure Genetics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Cure Genetics \/ Frametact","highestDevelopmentStatusID":"3","companyTruncated":"Cure Genetics \/ Frametact"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Expanded Collaboration","leadProduct":"CRISPR-based Gene Editing Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"PharmEnable","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Heptares \/ PharmEnable","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Heptares \/ PharmEnable"},{"orgOrder":0,"company":"Base4 Biotechnology","sponsor":"Servier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Base4 Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Base4 Biotechnology \/ Servier","highestDevelopmentStatusID":"3","companyTruncated":"Base4 Biotechnology \/ Servier"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Sibylla Biotech \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biocytogen \/ Neurocrine Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Reservoir Neuroscience","sponsor":"Kizoo Technology Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Reservoir Neuroscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Reservoir Neuroscience \/ Kizoo Technology Capital","highestDevelopmentStatusID":"3","companyTruncated":"Reservoir Neuroscience \/ Kizoo Technology Capital"},{"orgOrder":0,"company":"Bit Bio","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bit Bio \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"AbCellera","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ Biogen","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Biogen"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"BigHat Biosciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Creyon Bio","sponsor":"Cajal Neuroscience","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Creyon Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Creyon Bio \/ Cajal Neuroscience","highestDevelopmentStatusID":"3","companyTruncated":"Creyon Bio \/ Cajal Neuroscience"},{"orgOrder":0,"company":"Cerevance","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Cerevance","amount2":1.1299999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.1299999999999999,"dosageForm":"","sponsorNew":"Cerevance \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Cerevance \/ Merck & Co"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sosei Group Corporation","amount2":1.2,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.2,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Sosei Group Corporation \/ AbbVie Inc"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Ascidian Therapeutics","amount2":1.8400000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":1.8400000000000001,"dosageForm":"","sponsorNew":"Ascidian Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Ascidian Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alchemab","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"Antibody-based Therapy","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Alchemab \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Iktos","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"3","companyTruncated":"Iktos \/ Italfarmaco S.p.A"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"National Institutes of Mental Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Rumi Scientific \/ National Institutes of Mental Health","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ National Institutes of Mental Health"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
